TUCAN and Chemotherapy Resistance in Lung Cancer
Author Information
Author(s): Agnieszka Checinska, Giuseppe Giaccone, Bas SJ Hoogeland, Carlos G Ferreira, Jose A Rodriguez, Frank AE Kruyt
Primary Institution: VU University Medical Center
Hypothesis
Does TUCAN inhibit caspase-9 and affect chemosensitivity in non-small cell lung cancer (NSCLC) cells?
Conclusion
TUCAN does not inhibit procaspase-9 and does not determine sensitivity to cisplatin in NSCLC cells.
Supporting Evidence
- TUCAN was found to be highly expressed in NSCLC cells compared to SCLC cells.
- No interaction between TUCAN and procaspase-9 was detected.
- Down-regulation of TUCAN did not restore cisplatin-induced caspase-9 activation.
Takeaway
The study looked at a protein called TUCAN to see if it helps cancer cells resist treatment. It turns out TUCAN doesn't help with that.
Methodology
The study used Western blotting, RNA interference, and apoptosis assays to investigate TUCAN's role in caspase-9 inhibition.
Limitations
The study did not explore other potential inhibitors of caspase-9 in NSCLC cells.
Statistical Information
P-Value
p = 0.000
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website